Novel CSF1R-inibitor drugs
Technology
Our researchers at NTNU have synthesized novel small molecule inhibitors with great selectively towards the tyrosine kinase receptor, CSF1R. CSF1R is a class III receptor tyrosine kinase and member of the platelet-derived growth factor (PDGF) receptor family along with FLT3, c-KIT, and PDGF-α and -β receptors. CSF1R is expressed primarily on phagocytes (monocytes, macrophages, osteoclasts and dendritic cells) where its activation is crucial for their growth and differentiation during immune responses. In collaboration with the Lead Discovery Center (Dortmund) we optimize and refine our small molecule inhibitors into lead drug candidates valuable for handling neurodegenerative diseases, inflammatory diseases as well as combinatory treatment of cancer.
Market
The global neurodegenerative market size alone was estimated to USD 612 billion in 2022 and is expected to grow at a CAGR of 4.2%. Future demand for drugs in prophylaxis and treatment is driven by an increasing geriatric population.
Uniqueness
- High selectivity
- High plasma levels over time (slow clearance)
- Ideal BBB penetration
Status
- Ongoing animal model verifications
- Patents pending
- Seeking commercial partners and licensees
